Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

This study has been completed.

Sponsor:

Collaborator:

National Cancer Institute (NCI)

Information provided by:

Cancer and Leukemia Group B

ClinicalTrials.gov Identifier:

NCT00053196

First received: January 27, 2003

Last updated: April 5, 2011

Last verified: April 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	August 2010
Primary Completion Date:	November 2006 (Final data collection date for primary outcome measure)

Publications:

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C. Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002). Biol Blood Marrow Transplant. 2010 Jul 29; [Epub ahead of print]

Bashey A, Owzar K, Johnson JL, et al.: Reduced-intensity allogeneic transplantation after failure of autologous transplantation: a prospective multi-center CALGB study. [Abstract] Blood 108 (11): A-3122, 2006.

To Top